Docket No.: 57942.010001 02-10-2003 FORM PTO-1595 (Modified) U.S. DEPARTMENT OF COMMERCE (Rev. 03-01) Patent and Trademark Office OMB No. 0651-0027 (exp.5/31/2002) P08A/REV03 102362051 Tab settings → → To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof. 2. Name and address of receiving party(ies): 1. Name of conveying party(ies): **Aventis Pharma Deutschland GmbH** Name: Phospholipid GmbH Address: Nattermannallee 1 ☐ Yes ☒ No Additional names(s) of conveying party(ies) 3. Nature of conveyance: Merger City: Koln (Cologne) ☐ Change of Name State/Prov.: ☐ Security Agreement ZIP: 50829 Country: Fed. Rep. Germany ☐ Other Execution Date: 5/01/02 ☐ Yes ☑ No Additional name(s) & address(es) 4. Application number(s) or patent numbers(s): If this document is being filed together with a new application, the execution date of the application is: B. Patent No.(s) Patent Application No. Filing date 6.278.004 ☐ Yes 🗵 No Additional numbers 5. Name and address of party to whom correspondence 6. Total number of applications and patents involved? concerning document should be mailed: Name: Herbert H. Finn, Esq. 7. Total fee (37 CFR 3.41):....\$ 40.00 38139 Registration No. ⊠ Enclosed - Any excess or insufficiency should be credited or debited to deposit account Address: GREENBERG TRAURIG, P.C. ☐ Authorized to be charged to deposit account 77 West Wacker Drive 8. Deposit account number: **Suite 2500** State/Prov.: IL 50 2428 City: Chicago ZIP: 60601 (Attach duplicate copy of this page if paying by deposit account) Country: USA

2/07/2003 ECOOPER 00000241 6278004

DO NOT USE THIS SPACE

9-6144 ment and signature. 40.00 BP

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Herbert H. Finn

Name of Person Signing

Signature

Date

ASSIGNMENT OF PATENT RIGHTS

BE IT KNOWN THAT in consideration of the sum of One Dollar (\$ 1.00) and other good and valuable consideration, the receipt of which is hereby acknowledged, Aventis Pharma Deutschland GmbH, a corporation of Germany, hereinafter called ASSIGNOR, has as of May 1st,2002, sold, assigned, and transferred to Phospholipid GmbH, a corporation of Germany, and its successors and assigns, all hereinafter called ASSIGNEE:

All right, title and interest in the United States and throughout the world in and to any inventions, patent rights, patents, and applications for patent, including without limitation the entire right, title, and interest in and to the United States patent and applications for United States patents noted in Schedule A attached hereto and made a part hereof, and the entire right, title, and interest in the United States and throughout the world in and to the inventions to which said patents and applications pertain, and in and to any corresponding foreign patents or patent applications, registrations, or inventor's certificates, together with all of the rights and privileges granted and secured by said patents or patent applications, registrations, or certificates, including without limitation all claims, demands, and rights of action which ASSIGNOR may have had against others on account of any past infringement of any of said patents, with the right in ASSIGNEE to sue for and obtain all relief to which ASSIGNOR may have been entitled by reason of any such past infringement, said entire right, title, and interest to be held and enjoyed by ASSIGNEE for its own use and benefit and for the use and

> PATENT REEL: 013718 FRAME: 0976

benefit of its successors and assigns, to the full end of the term for which said patents, registrations, or certificates may be granted, as fully and entirely as the same would have been held and enjoyed by said ASSIGNOR had this assignment and sale not been made. The Commissioner of Patents and Trademarks is hereby authorized and requested to issue the Letters Patent which may mature from the aforesaid applications to the said ASSIGNEE, as the assignee of said entire right, title, and interest in and to the same.

Aventis Pharma Deutschland GmbH

Title: General Manager

Signed and acknowledged in the presence of:

Addressimin Wendel

Max-Ernst-Str. 29

D-50859, Köln / Germany

Name: Address:

Gudrun Lux

Mozartstr. 33

D-50259 Pulheim / Germany

PATENT REEL: 013718 FRAME: 0977

SCHEDULE A

PATENTS and PATENT APPLICATIONS

Patent (P) or Patent No. or

Application (A) Application No.

File/Issue ___Date___

(P)

6,278,004

August 21, 2001

PATENT **REEL: 013718 FRAME: 0978**

RECORDED: 02/06/2003